Company news
Corcept Therapeutics Incorporated news in 2022
Corcept Therapeutics Incorporated's news releases, calls and decks from 2022, newest first.
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
December 7, 2022
Corcept Therapeutics Provides Miricorilant Clinical Development Update
December 7, 2022
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
October 10, 2022
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
June 28, 2022
Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
June 5, 2022
Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update
May 4, 2022
Corcept Therapeutics Announces Appointment of Three Senior Leaders
April 6, 2022
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain
April 3, 2022
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer
March 29, 2022
Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022
February 28, 2022
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update
February 14, 2022
Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call
February 7, 2022